TABLE OF CONTENTS
HANC ANNOUNCEMENTS
NETWORK ANNOUNCEMENTS
HANC PROGRAM UPDATES
CONFERENCES AND MEETINGS
|
|
|
|
AIDS 2024:
Miss Molly Moon takes Munich
|
|
|
|
|
|
|
Miss Molly Moon lands in Munich for AIDS 2024.
|
|
Miss Molly Moon and Dr. Asa Radix present on trans representation in HIV prevention research in the Global Village.
|
|
Irkoy berri! Miss Molly connects with Moctar Gado from Niger, where Molly served in the US Peace Corps. Her Zarma is still fluent.
|
|
HANC Deputy Director Brian Minalga (aka Molly Moon) and Cindra Feuer, Senior Program Manager at AVAC
|
|
|
|
Brian Minalga and Miss Molly Moon represented HANC at AIDS 2024. Miss Molly appeared at the HPTN/HVTN booth in the Global Village, where she was interviewed by Dr. Asa Radix about trans and gender-diverse inclusion in HIV research.
On Day 3 of the conference, Brian provided media coverage on HIV.gov, interviewing the likes of Carl Dieffenbach (DAIDS), Tori Cooper (PACHA), and Jono Mermin (CDC) on topics such as lenacapavir for HIV prevention, the inclusion of people who use drugs in HIV research, and leveraging the power of the DAIDS-funded HIV research Networks to address global pandemics.
AIDS 2024 was an amazing opportunity to connect with our colleagues and friends in the HIV response, and we look forward to seeing you again soon!
|
|
|
|
Twice-yearly Lenacapavir or Daily Oral Entricitabine/Tenofovir for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study
|
|
|
|
|
ZERO HIV Infections in Cisgender Women receiving LEN
|
|
|
|
HANC Deputy Director Brian Minalga interviews Director of DAIDS, Dr. Carl Dieffenbach and catches up on the PURPOSE 1 study results, representation of people who use drugs in clinical trials, and future vision for HIV research.
|
|
|
|
We can't stop talking about Lenacapavir at AIDS 2024!
HANC Deputy Director Brian Minalga gets the scoop in Munich.
|
|
|
|
|
|
Russell Campbell, HANC Director, is featured in the Network Member Spotlight of the HPTN July 2024 Newsletter
Read the full article here.
|
|
|
|
|
|
|
|
|
|
|
Houston Advancing Research Team Community Advisory Board (HART-CAB) members Caleb Brown (L) and Kevin Aloysius (R) had lots of fun talking about the CAB to the public attending the Houston PRIDE festival. They were able to inform of the public about current trials going on, how their voice can impact the future of clinical trials and how they can become involved. Over 200 people stopped by the booth!
|
|
|
|
|
|
|
HVTN takes on AIDS 2024!
NIH's Dr. Carl Dieffenbach joins us for another conversation on research highlights from #AIDS2024. He is joined by Dr. Michele Andrasik of the HIV Vaccine Trials Network & COVID-19 Prevention Network to discuss Cab-LA safety in pregnancy, the plenary session on HIV vaccine, and lessons learned to improve service delivery for HIV prevention and treatment.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On Tuesday, July 23, Dr. Raphael Landovitz, incoming HPTN principal investigator and HPTN 083 protocol
chair, presented an analysis from HPTN 083. In an open-label extension of HPTN 083, a study among cisgender men and transgender women (TGW) who have sex with men, the clinical utility of RNA viral load testing during follow-up (as part of HIV testing algorithms) was examined in participants on long-acting injectable cabotegravir (CAB-LA). The analysis showed that a single, isolated positive HIV viral load test result, while uncommon, was frequently a false positive result. Repeat HIV viral load testing on a new blood sample can clarify whether the initial positive result indicates actual HIV infection.
|
|
|
|
|
|
On Thursday, July 25, Dr. Sinead Delany-Moretlwe, incoming HPTN principal investigator and HPTN 084 protocol
chair, and Dr. Mark Marzinke, HPTN Laboratory Center co-principal investigator presented new safety and pharmacokinetic (PK) findings for long-acting injectable cabotegravir (CAB-LA) when used before and during pregnancy. The findings show that CAB-LA used as pre-exposure prophylaxis (PrEP) was generally well tolerated and generally safe for both pregnant cisgender women and their babies. In addition, PK findings suggest that no dose changes are needed when using CAB-LA during pregnancy. To date, none of the women who became pregnant and continued to receive CAB acquired HIV during pregnancy.
|
|
|
|
(L-R) Dr. Wafaa El-Sadr, HPTN principal investigator, and Dr. Larry Corey, HVTN principal investigator
In addition to the presented data, the HPTN collaborated with the HIV Vaccine Trials Network (HVTN) to host a ‘networking zone’ in the Global Village, where speakers discussed research priorities and prevention successes.
Presentations and posters will be added to the HPTN website when available.
The host city for AIDS 2026 will be announced later this year.
|
|
|
|
Early Career Investigator Program
Applications are now open for the IMPAACT Early Career Investigator Program. Those interested in building research skills and supporting the IMPAACT Network’s goal to improve health outcomes for infants, children, adolescents, and pregnant and postpartum people who are impacted by or living with HIV, tuberculosis, and other HIV-related conditions are encouraged to apply.
Eligibility criteria, key dates, and application materials can be found here. Applications are due by Tuesday, 01 October 2024.
|
|
IMPAACT Network Annual Meeting
Only two months left until the IMPAACT Network Annual Meeting!
Registration will open on Monday, 29 July 2024.
This year’s meeting will be held 22-27 September at the Crystal Gateway Marriott in Arlington, VA. To register for the meeting, view a preliminary agenda, and find other information, please visit the Annual Meeting page on our website.
|
|
|
|
|
|
|
|
DAIDS Director Dr. Carl Dieffenbach (left) with IMPAACT Network Chair Dr. Sharon Nachman (right)
|
|
|
|
|
|
Behavioral and Social Sciences
|
|
Greg Davis
HANC
Project Manager
|
Behavioral Science Consultative Group: The Behavioral Science Consultative Group (BSCG) will meet in person in Seattle on August 2. The meeting will result in the development of recommendations documents.
Financial Disclosure Working Group: The Financial Disclosure Working Group is preparing for the annual solicitation which will occur on September 20, 2024.
|
|
|
|
|
|
|
Greg Davis
HANC
Project Manager
|
|
Russell Campbell
HANC Director
|
Community Partners: Community Partners (CP) is meeting face-to-face in September in the Washington, DC area.. The CP Executive Committee is finalizing the agenda. The agenda is packed and includes an important discussion with Dr. Carl Dieffenbach. CP will spend the second day of the meeting focusing on developing its 2025 work plan. CP will also reveal a new Community Partners logo at the face-to-face meeting.
TB Vaccine Community Engagement Strategy WG: The TB Vaccine Community Engagement Strategy Work Group is looking for a new time for its monthly meetings.
|
|
|
|
Cross-Network Coordination
|
|
Kathleen Pescasio
HANC Cross-Network
Project Manager
|
The Cross-Network Communications Working Group (CWG) shared network engagements from the recent ACTG and HPTN Annual Meetings. The group also discussed poster presentations, oral presentations, press releases, and media plans for upcoming conferences. The CWG continues to share experiences with graphic design and communications tools.
The Cross-Network Site Coordinators Working Group (SCWG) discussed strategies for site success and training and mentorship needs. At the last meeting, group members shared valuable input on the benefits of real-time support and community engagement, and various action items were proposed. The SCWG will continue to discuss best practices for improving communication lines and support structures across networks.
The Cross-Network Data Management Center Working Group (DMCWG) discussed several ongoing initiatives and updates on survey software tools and study engagement systems. Frontier Science is progressing with their pilot of Medidata Detect, and SCHARP shared their completion of a pilot project for EMR data extraction.
|
|
|
|
|
|
|
Tyler Brown
HANC Laboratory
Project Manager
|
Attention PBMC Processing Laboratories: A new version of the PBMC Processing SOP (v7.0) will be published on the HANC website (https://www.hanc.info/resources/sops-guidelines-resources/laboratory/cross-network-pbmc-processing-sop.html) on Monday, August 5th. Translations of the new SOP in Spanish, Portuguese, Thai, and Vietnamese will be available through the same link by August 12th. The SOP will go into effect on August 19th.
The Lab Focus Group convened in July to address laboratory supply shortages, discuss guidelines for laboratory document archiving, and discuss the upcoming publication of the Cross-Network PBMC Processing SOP.
|
|
|
|
|
|
|
Brian Minalga
HANC
Deputy Director
|
|
Cat Banobi
Legacy
Project Manager
|
|
Gabriella Olague
HANC
Project Coordinator
|
July 30: Legacy Project Director, Brian Minalga, is quoted in an article published in STAT, covering a
recent publication that Brian co-authored in JIAS as well as a range of issues focused on HIV research with trans and gender-diverse people.
Speakers:
Dr. Hannah Kuper, London School of Hygiene and Tropical Medicine
Tafadzwa Maseva, Zimbabwe Network for Disability
Brian Minalga, Office of HIV/AIDS Network Coordination (HANC)
Sarah Mwikali, Gifted Community Centre
Moderators:
JD Davids, Strategies for High Impact / Long COVID Justice
Patriciah Jeckonia, LVCT Health
August 22: The Legacy Project’s New Investigators Working Group is hosting a webinar entitled "What to Expect as a New Investigator," featuring Dr. Monica Gandhi of UC San Francisco.
This webinar is intended for new investigators; Dr. Gandhi will share valuable insights and expertise to further prepare new investigators for careers as investigators at clinical trial sites. If you are interested in attending the webinar, please contact Cat Banobi at cbanobi@fredhutch.org
Date: August 22, 2024
Time: 7-8 AM Pacific Time
|
|
|
|
|
|
Community Partners Meeting (Arlington, USA)
|
|
|
|
IMPAACT Annual Network Meeting (Arlington, USA)
|
|
|
|
|
